Literature DB >> 28664622

Subclinical atherosclerosis in low Framingham risk HIV patients.

Rafael León1, Sergio Reus1, Nicolás López2, Irene Portilla1, José Sánchez-Payá3, Livia Giner1, Vicente Boix1, Esperanza Merino1, Diego Torrús1, Óscar Moreno-Pérez4, Joaquín Portilla1.   

Abstract

BACKGROUND: Pathogenesis of atherosclerosis is complex, and differences between HIV-infected patients and general population cannot be completely explained by the higher prevalence of traditional cardiovascular risk factors. We aimed to analyse the association between inflammation and subclinical atherosclerosis in HIV patients with low Framingham risk score.
MATERIALS AND METHODS: Case-control study.
SETTING: Outpatient Infectious Diseases clinic in a university hospital.
SUBJECTS: HIV-1-infected patients aged > 35 years receiving antiretroviral treatment with viral load < 50 copies/mL and Framingham risk score < 10%. EXCLUSION CRITERIA: inflammatory diseases; dyslipidaemia requiring statins; smoking > 5 cigarettes/day; diabetes; hypertension; vascular diseases. MAIN OUTCOME: subclinical atherosclerosis determined by ultrasonography: common carotid intima-media thickness greater than 0·8 mm or carotid plaque presence. Explanatory variables: ribosomal bacterial DNA (rDNA), sCD14, interleukin-6 (IL-6) and TNF-α.
RESULTS: Eighty-four patients were included, 75% male, mean age 42 years and mean CD4+ cells 657 ± 215/mm3 . Median Framingham risk score was 1% at 10 years (percentile 25-75: 0·5-4%). Eighteen patients (21%) had subclinical atherosclerosis; the associated factors were older age (P = 0·001), waist-hip ratio (P = 0·01), time from HIV diagnosis (P = 0·02), rDNA (P = 0·04) and IL-6 (P = 0·01). In multivariate analysis, OR for subclinical atherosclerosis was 7 (95% CI, 1.3-40, P = 0.02) and 9 (95% CI, 1.0-85, P = 0.04) for patients older than 44 years and IL-6 > 6·6 pg/mL, respectively.
CONCLUSIONS: Well-controlled HIV patients with low Framingham risk score have a high prevalence of subclinical carotid atherosclerosis, and the main risk factors are age and inflammation. These patients are not receiving primary prophylaxis for cardiovascular events according to current guidelines.
© 2017 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Keywords:  HIV; inflammation; intima-media thickness; microbial translocation; subclinical atherosclerosis

Mesh:

Substances:

Year:  2017        PMID: 28664622     DOI: 10.1111/eci.12780

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  3 in total

Review 1.  How Monocytes Contribute to Increased Risk of Atherosclerosis in Virologically-Suppressed HIV-Positive Individuals Receiving Combination Antiretroviral Therapy.

Authors:  Anthony Jaworowski; Anna C Hearps; Thomas A Angelovich; Jennifer F Hoy
Journal:  Front Immunol       Date:  2019-06-19       Impact factor: 7.561

2.  Subclinical atherosclerosis and associated risk factors among HIV-infected adults in Jos, North Central Nigeria: a cross-sectional study.

Authors:  Lucius Chidiebere Imoh; Charles Chibunna Ani; Kuleve Othniel Iyua; Alfred Ibu Odo; Ganiyu Adeniyi Amusa; Godwin Osawaru Osaigbovo; Christian Ogoegbulam Isichei; Oche Ochai Agbaji; Godwin Imade; Ayuba Ibrahim Zoakah; Basil Nwaneri Okeahialam; Atiene Solomon Sagay
Journal:  Pan Afr Med J       Date:  2020-12-31

Review 3.  Examining Relationships between Metabolism and Persistent Inflammation in HIV Patients on Antiretroviral Therapy.

Authors:  Duale Ahmed; David Roy; Edana Cassol
Journal:  Mediators Inflamm       Date:  2018-09-27       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.